Kodiak Sciences Inc.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Previously recorded as Oligasis, LLC (to 2015)
3
Ending by 2030
Feb 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jan 30, 2027The maintenance fee for Butyrylcholinesterase zwitterionic polymer conjugates (US 10,363,290) comes due Jan 30, 2027. Unpaid by Jul 30, 2027, it lapses early.
- 1 fee due May 21, 2027The maintenance fee for Multifunctional Zwitterionic Polymer Conjugates (US 11,819,531) comes due May 21, 2027. Unpaid by Nov 22, 2027, it lapses early.
- 1 fee due Aug 27, 2027The maintenance fee for Methods of Treating an Eye Disorder (US 11,912,784) comes due Aug 27, 2027. Unpaid by Feb 28, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,846,021 | Acryloyloxyethylphosphorylcholine containing polymer conjugates and their preparation In force · From the USPTO record | In force | From the USPTO record | |
| US 8,765,432 | Targeted Drug Phosphorylcholine Polymer Conjugates In force · High confidence | In force | High confidence | |
| US 11,819,531 | Multifunctional Zwitterionic Polymer Conjugates In force · High confidence | In force | High confidence | |
| US 11,590,235 | Factor VIII Zwitterionic Polymer Conjugates In force · Medium confidence | In force | Medium confidence | |
| US 12,214,044 | Factor VIII zwitterionic polymer conjugates In force · From the USPTO record | In force | From the USPTO record | |
| US 10,702,608 | Factor VIII zwitterionic polymer conjugates In force · From the USPTO record | In force | From the USPTO record | |
| US 9,840,553 | Dual Pdgf/VEGF Antagonists In force · Medium confidence | In force | Medium confidence | |
| US 11,155,610 | Dual Pdgf/VEGF Antagonists In force · Medium confidence | In force | Medium confidence | |
| US 10,363,290 | Butyrylcholinesterase zwitterionic polymer conjugates In force · From the USPTO record | In force | From the USPTO record | |
| US 11,066,465 | Antibodies and Conjugates Thereof In force · High confidence | In force | High confidence |
Also on record, not counted in the 15: 1 lapsed for an unpaid fee. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
7 pending · 3 abandoned · 5 no status recorded